The Life Science Feed
Deep dives with clinicians, researchers, and industry leaders.
All episodes
Wearable Devices Detect CAR-T CRS Hours Earlier, Improving Patient Outcomes
Wearable devices identify cytokine release syndrome (CRS) in CAR-T cell therapy recipients hours before clinical recognition, enabling earlier intervention and potentially reducing severe complications.
Breast NeoplasmsTucatinib Extends PFS in HER2-Positive Breast Cancer, No New Safety Signals
Tucatinib demonstrated extended progression-free survival in HER2-positive breast cancer with a consistent safety profile, reinforcing its role.
Solid TumorsBowhead Whale Longevity Genes Offer Clues for Cancer, Aging
Insights from the bowhead whale's exceptional lifespan and cancer resistance point to novel genetic pathways for human anti-aging and oncology research.
Half of Older Adults With Metastatic Lung Cancer Receive No Systemic Treatment
8 min readProstate Care: Balancing Immediate Relief with Long-Term Retreatment
10 min readGenetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy
12 min readGiredestrant Improves Breast Cancer Survival Regardless of Menopause
8 min readBiomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
9 min readAlpha-Emitting Radioantibody Lowers PSA in CRPC
15 min read
Hypotension Linked to Increased Alzheimer's Disease Risk
New research indicates that mid-life hypotension is a significant cardiovascular risk factor for later-life Alzheimer's disease, challenging prior assumptions.
Heart FailureUniversal Heart Failure Definition Issued by Global Societies
Four major cardiology societies released a universal definition of heart failure, aiming to standardise diagnosis and research across the globe.
Coronary Artery DiseaseNovel Therapies Target Atherogenic Lp(a) Particle
Emerging therapeutic strategies are shifting focus from LDL cholesterol to apoB, targeting Lp(a) and other atherogenic particles.
Clopidogrel and Omeprazole: Re-evaluating Concomitant Use Risk
7 min readVitamin K2 Supplementation May Curb Coronary Calcification
12 min readAI-Assisted Fetal Echocardiography Improves Early CHD Detection
8 min readESC Cardio-Oncology 2026: Key Sessions and Anticipated Focus Areas
7 min readLipoprotein(a) Risk: Define, Test Early, Optimise Management
7 min readHeat-Attributable CVD Years of Life Lost Projected to Rise Through 2050
8 min read
Isaacs Emphasizes 'Human Touch' in Diabetes Care Beyond Technology
Diana Isaacs, PharmD, an ADA award winner, advocates for integrating empathetic, patient-centered approaches with advanced diabetes technology to improve outcomes.
Diabetes Mellitus Type 2Elecoglipron Oral GLP-1 Reduces Glucose, Weight in Phase 2
Elecoglipron, an investigational oral GLP-1 receptor agonist, demonstrated reductions in HbA1c and body weight in phase 2 trials.
ObesityBariatric Surgery: Efficacy and Emerging Pharmacotherapies in Obesity Management
Bariatric surgery remains a highly effective intervention for severe obesity, but new pharmacotherapies are challenging its dominance.
Medicare to Cover New Osteoporosis Diagnostic Screening Test
8 min readOmnipod 5 Improves CGM Metrics, Reduces Hypoglycaemia in Diabetes
12 min readCombination GLP-1RA and SGLT2i May Offer Additive Benefits in T2DM
10 min readMedically Tailored Meals Cut HbA1c More Than Subsidies in Type 2 Diabetes
11 min readGLP-1 Receptor Agonist Use Varies Widely for Youth Type 2 Diabetes
8 min readFoundayo Confers Greater HbA1c Reduction Than Farxiga, Ozempic Pill in T2D
8 min read
Huntington's Disease Therapy Faces Regulatory Setbacks, Clinical Impact
A novel investigational therapy for Huntington's disease has encountered significant regulatory hurdles, prompting re-evaluation of its clinical development pathway.
Migraine DisordersEptinezumab Improves Cognitive Symptoms in Migraine Patients
Eptinezumab significantly reduced cognitive symptoms in patients with migraine, offering a new dimension of relief beyond headache frequency.
Parkinson DiseaseDopamine Agonists: A Fading Role in Parkinson's Treatment?
Dopamine agonists, once a cornerstone for Parkinson's disease, face increasing scrutiny due to neuropsychiatric side effects and limited long-term motor benefits.
Fast Five Quiz: Assessment of Tardive Dyskinesia
7 min readGLP-1s do not improve migraines, but reduce healthcare utilisation
7 min readBrief Brain Stimulation Effective for Depression in Parkinson's Disease
8 min readNew Parkinson's Drug Offers Sustained Levodopa Levels
9 min readGlucosamine/Chondroitin Tied to Faster AD Progression
7 min readMigraine Linked to Increased Vascular Dementia Odds in Observational Data
11 min read
Munich, DEAug 28 – 31UpcomingEASD 2026
Madrid, ESSep 9 – 12UpcomingERS 2026
Copenhagen, DKSep 12 – 15UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026
Vienna, ATOct 3 – 7UpcomingAHA 2026
Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026
Stockholm, SEJun 11 – 14PastEULAR 2026
London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30UpcomingESC 2026Munich, DEAug 28 – 31UpcomingEASD 2026Madrid, ESSep 9 – 12UpcomingERS 2026Copenhagen, DKSep 12 – 15UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026Vienna, ATOct 3 – 7UpcomingAHA 2026Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026Stockholm, SEJun 11 – 14PastEULAR 2026London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30
Metabolic Dysfunction Associated Steatotic Liver Disease: An Overview
A recent review outlines the mechanisms, diagnosis, and management of metabolic dysfunction associated steatotic liver disease (MASLD) in adults.
Liver CirrhosisEASL 2026 Forum: Enhancing Patient-Clinician Communication
The EASL 2026 Patient & Advocate Forum addresses critical gaps in patient-clinician communication and interprofessional collaboration.
Liver CirrhosisEASL 2026: Alcohol Policy Action Needed for Liver Disease
The European Health Alliance on Alcohol advocates for policy changes to mitigate alcohol-related liver disease, emphasizing the gap between clinical evidence and public health action.
Alcohol and Sugar: A Dual Metabolic Challenge for Patients
7 min readEASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
7 min readVariceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
8 min readLiver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
7 min readEASL Congress 2026: Key Trials to Watch in Liver Disease Management
7 min read
New Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
7 min readMonoclonal Antibodies May Complicate Transfusion Testing
7 min readBlood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections
7 min readChemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
8 min readPersonalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
7 min readMacrophages: Dual Role in Haematological Malignancies Explored
7 min readMolecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
7 min readITP Management: Bridging Clinician and Patient Perspectives
7 min readCLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
8 min readMyelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
8 min read
Sleep Disruption and Fear Drive Chronic Rheumatic Pain
11 min readPodcast: Why Cheaper Humira Alternatives Face Resistance
ListenPodcast: Stopping Spinal Fusion Or Protecting The Gut?
ListenPodcast: Chasing Absolute Zero In Rheumatoid Arthritis
ListenPodcast: The ORAL Surveillance JAK Inhibitor Controversy
Listen
Air Embolism: Two Cases After Percutaneous Lung Biopsy
7 min readSingle Question May Flag Poor Quality Sleep in Patients
9 min readPembrolizumab Reduces Pulmonary AEs vs Chemotherapy in NSCLC
8 min readDupilumab Superior to Omalizumab in High-Biomarker Asthma
7 min readATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
8 min read
Rifadin Syrup Under Review for Carcinogen Concerns
7 min readPublic Health Measures Significantly Reduced COVID-19 Incidence
8 min readData Integrity Concerns Raised in Pfizer's COVID-19 Vaccine Trial
7 min readVaccine Cold Chain Integrity Underpins Vaccine Security
8 min readCurrent and Emerging Therapies for Pulmonary Tuberculosis
6 min read
Prior Authorization Delays Atopic Dermatitis Treatment Access
13 min readPatient-Reported Factors Redefine Alopecia Areata Severity
7 min readScalp Lesions: Rare Malignancies Mimic Benign Conditions
7 min readDown Syndrome: Skin Conditions Demand Dermatologists’ Attention
7 min readGLP-1 Receptor Agonists and Psoriatic Disease: A Deep Dive
7 min readBRINSUPRI® First Therapy Approved for NCFB at ATS 2026
7 min readDRC Ebola Outbreak Exposes Global Health Underfunding Consequences
7 min readGoat Milk Formula Linked With Less Atopic Dermatitis
7 min read
Early Intervention in SLE/LN Reduces Long-Term Damage
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Early Breast Cancer at ASCO 2026: Trials to Watch
CAR T: Speed and Reliability Critical for Patient Outcomes
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations
New Biologic Offers Option for Severe Eosinophilic Asthma
Low Alkaline Phosphatase: Recognizing Clinical Consequences
CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
Epithelial Dysfunction: A Unified Target in Airway Disease Management
AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes
Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
AI in Oncology: Practical Applications Transforming Cancer Care
ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
EGPA: Early Recognition & Targeted Intervention Improve Outcomes
Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
ILD Diagnosis and Management: A Practical ATS 2026 Update
SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
AML: Fitness, Not Age, Predicts IC Eligibility at EHA 2026
Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases
AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration
Immunological Insights Inform ILD & Transplant Outcomes
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma
DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy
Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
How Immunotherapy Unmasks Invisible Lung Cancer
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies
Ventilator Management: Foundations for Bedside Implementation
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
Infection Prevention Critical in Hematological Malignancies
VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026
DLBCL Treatment: Emerging Targeted Therapies at EHA 2026
CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
Novel Biomarkers Improve Pediatric Solid Tumor Detection
CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
EASL 2026: PSC Therapies Advance Beyond Symptom Management
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk
AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
ASCO 2026: Anticipating Advances in Oncology Treatment
Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies
Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
Inflammation Drives Sickle Cell Disease Pathophysiology
EHA 2026: Anticipating Advances in Haematological Malignancies
B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
CD20-Targeted Therapies Remain Central to NHL Management
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
Outsmarting Shape-Shifting Lung Cancer Resistance
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies
CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights
Infection Prevention Critical in Hematological Malignancies
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
CML Survivorship: Beyond Survival to Quality of Life
ATS 2026: Ultrasound Education Advances for Clinical Practice
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
RA Treatment Optimisation: Applying Two Decades of Progress
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
CLL First-Line Therapy: Case-Based Insights from EHA 2026
Desmopressin Dosing Refined for Central Diabetes Insipidus
Multidisciplinary Approach Improves Autoimmune ILD Management
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
Pediatric Pulmonary Research Gaps Highlighted for Global Health
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
Macrophages: Dual Role in Haematological Malignancies Explored
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
NDMM Treatment Advances: Quadruplet Regimens Show Efficacy
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option
BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
Sarcoidosis: Current Understanding of Diagnosis and Management
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
Multidisciplinary Care Improves Spondyloarthritis Outcomes
EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
Hypercortisolism: Emerging Diagnostic and Management Insights
CLL: EHA 2026 to Address Unmet Needs in Treatment Selection
SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
XLH Management: Rheumatology Must Adapt at EULAR 2026
Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
Classic CAH: New Approaches to Glucocorticoid Dosing
ITP Management: Bridging Clinician and Patient Perspectives
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months
Novel Approaches in R/R MM: Expert Perspectives from EHA 2026
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
Triple Therapy Optimises COPD Outcomes at ATS 2026
Obesity Management Improves Psoriatic Disease Outcomes
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
EASL 2026 Forum: Enhancing Patient-Clinician Communication
RA Care: Navigating Treatment Choices at EULAR 2026
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
Inluriyo™ and Verzenio® Presentations at ASCO 2026
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
Caplacizumab Improves iTTP Outcomes in Real-World Settings
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
More Breast Cancer Patients Can Skip Axillary Dissection
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
Pediatric Advanced Bronchoscopy: Precision in Airway Management
NDMM Treatment Optimisation: Communication Key to Individualisation
EULAR 2026: Psoriatic Disease Spectrum Highlights
Real-World Data Confirms Proximal Complement Inhibition in PNH
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma
Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
EASL 2026: Alcohol Policy Action Needed for Liver Disease
AI Foundation Models Enhance Diagnostic Insights in Oncology
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
Lupus Management: Progress and Persistent Challenges at EULAR 2026
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma
AML Treatment Strategies: Optimising Outcomes in a Complex Disease
ICI Dissemination Challenges Highlighted at ASCO 2026
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
Evolving Infection Prevention in HSCT and Cellular Therapies
MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies
Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
Early Intervention in SLE/LN Reduces Long-Term Damage
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Early Breast Cancer at ASCO 2026: Trials to Watch
CAR T: Speed and Reliability Critical for Patient Outcomes
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations
New Biologic Offers Option for Severe Eosinophilic Asthma
Low Alkaline Phosphatase: Recognizing Clinical Consequences
CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
Epithelial Dysfunction: A Unified Target in Airway Disease Management
AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes
Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
AI in Oncology: Practical Applications Transforming Cancer Care
ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
EGPA: Early Recognition & Targeted Intervention Improve Outcomes
Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
ILD Diagnosis and Management: A Practical ATS 2026 Update
SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
AML: Fitness, Not Age, Predicts IC Eligibility at EHA 2026
Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases
AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration
Immunological Insights Inform ILD & Transplant Outcomes
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma
DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy
Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
How Immunotherapy Unmasks Invisible Lung Cancer
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies
Ventilator Management: Foundations for Bedside Implementation
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
Infection Prevention Critical in Hematological Malignancies
VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026
DLBCL Treatment: Emerging Targeted Therapies at EHA 2026
CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
Novel Biomarkers Improve Pediatric Solid Tumor Detection
CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
EASL 2026: PSC Therapies Advance Beyond Symptom Management
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk
AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
ASCO 2026: Anticipating Advances in Oncology Treatment
Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies
Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
Inflammation Drives Sickle Cell Disease Pathophysiology
EHA 2026: Anticipating Advances in Haematological Malignancies
B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
CD20-Targeted Therapies Remain Central to NHL Management
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
Outsmarting Shape-Shifting Lung Cancer Resistance
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies
CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights
Infection Prevention Critical in Hematological Malignancies
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
CML Survivorship: Beyond Survival to Quality of Life
ATS 2026: Ultrasound Education Advances for Clinical Practice
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
RA Treatment Optimisation: Applying Two Decades of Progress
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
CLL First-Line Therapy: Case-Based Insights from EHA 2026
Desmopressin Dosing Refined for Central Diabetes Insipidus
Multidisciplinary Approach Improves Autoimmune ILD Management
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
Pediatric Pulmonary Research Gaps Highlighted for Global Health
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
Macrophages: Dual Role in Haematological Malignancies Explored
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
NDMM Treatment Advances: Quadruplet Regimens Show Efficacy
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option
BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
Sarcoidosis: Current Understanding of Diagnosis and Management
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
Multidisciplinary Care Improves Spondyloarthritis Outcomes
EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
Hypercortisolism: Emerging Diagnostic and Management Insights
CLL: EHA 2026 to Address Unmet Needs in Treatment Selection
SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
XLH Management: Rheumatology Must Adapt at EULAR 2026
Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
Classic CAH: New Approaches to Glucocorticoid Dosing
ITP Management: Bridging Clinician and Patient Perspectives
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months
Novel Approaches in R/R MM: Expert Perspectives from EHA 2026
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
Triple Therapy Optimises COPD Outcomes at ATS 2026
Obesity Management Improves Psoriatic Disease Outcomes
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
EASL 2026 Forum: Enhancing Patient-Clinician Communication
RA Care: Navigating Treatment Choices at EULAR 2026
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
Inluriyo™ and Verzenio® Presentations at ASCO 2026
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
Caplacizumab Improves iTTP Outcomes in Real-World Settings
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
More Breast Cancer Patients Can Skip Axillary Dissection
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
Pediatric Advanced Bronchoscopy: Precision in Airway Management
NDMM Treatment Optimisation: Communication Key to Individualisation
EULAR 2026: Psoriatic Disease Spectrum Highlights
Real-World Data Confirms Proximal Complement Inhibition in PNH
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma
Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
EASL 2026: Alcohol Policy Action Needed for Liver Disease
AI Foundation Models Enhance Diagnostic Insights in Oncology
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
Lupus Management: Progress and Persistent Challenges at EULAR 2026
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma
AML Treatment Strategies: Optimising Outcomes in a Complex Disease
ICI Dissemination Challenges Highlighted at ASCO 2026
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
Evolving Infection Prevention in HSCT and Cellular Therapies
MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies
Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
